User profiles for Alessandra Løchen
 | Alessandra LøchenPrincipal Epidemiologist, UKHSA Verified email at ukhsa.gov.uk Cited by 900 |
Adapting hospital capacity to meet changing demands during the COVID-19 pandemic
Background To calculate hospital surge capacity, achieved via hospital provision interventions
implemented for the emergency treatment of coronavirus disease 2019 (COVID-19) and …
implemented for the emergency treatment of coronavirus disease 2019 (COVID-19) and …
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
…, R Hisner, I Donovan-Banfield, H Hartman, A Løchen… - Nature, 2023 - nature.com
Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
coronavirus 2 (SARS-CoV-2), acts by inducing mutations in the virus genome during …
[HTML][HTML] Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: A mathematical modelling analysis
The worldwide endeavour to develop safe and effective COVID-19 vaccines has been
extraordinary, and vaccination is now underway in many countries. However, the doses available …
extraordinary, and vaccination is now underway in many countries. However, the doses available …
Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency
Streptococcus pneumoniae is a significant cause of otitis media, pneumonia, and meningitis.
Only seven of the approximately 100 serotypes were initially included in the pneumococcal …
Only seven of the approximately 100 serotypes were initially included in the pneumococcal …
Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases
…, R Hisner, I Donovan-Banfield, H Hartman, A Løchen… - medRxiv, 2023 - medrxiv.org
Molnupiravir, an antiviral medication that has been widely used against SARS-CoV-2, acts
by inducing mutations in the virus genome during replication. Most random mutations are …
by inducing mutations in the virus genome during replication. Most random mutations are …
Clinical characteristics and predictors of outcomes of hospitalized patients with coronavirus disease 2019 in a multiethnic London national health service trust: a …
Background Emerging evidence suggests ethnic minorities are disproportionately affected
by coronavirus disease 2019 (COVID-19). Detailed clinical analyses of multicultural …
by coronavirus disease 2019 (COVID-19). Detailed clinical analyses of multicultural …
Modelling intensive care unit capacity under different epidemiological scenarios of the COVID-19 pandemic in three Western European countries
Background The coronavirus disease 2019 (COVID-19) pandemic has placed enormous
strain on intensive care units (ICUs) in Europe. Ensuring access to care, irrespective of COVID-…
strain on intensive care units (ICUs) in Europe. Ensuring access to care, irrespective of COVID-…
Pneumococcal vaccines: host interactions, population dynamics, and design principles
NJ Croucher, A Løchen… - Annual review of …, 2018 - annualreviews.org
Streptococcus pneumoniae (the pneumococcus) is a nasopharyngeal commensal and
respiratory pathogen. Most isolates express a capsule, the species-wide diversity of which has …
respiratory pathogen. Most isolates express a capsule, the species-wide diversity of which has …
[HTML][HTML] Enhancing epidemiological surveillance of the emergence of the SARS-CoV-2 Omicron variant using spike gene target failure data, England, 15 November to …
When SARS-CoV-2 Omicron emerged in 2021, S gene target failure enabled differentiation
between Omicron and the dominant Delta variant. In England, where S gene target …
between Omicron and the dominant Delta variant. In England, where S gene target …
Comparative transmission of SARS-CoV-2 Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) variants and the impact of vaccination: national cohort study, England
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529)
rapidly replaced Delta (B.1.617.2) to become dominant in England. Our study …
rapidly replaced Delta (B.1.617.2) to become dominant in England. Our study …